Plop vs Aidy for Ulcerative Colitis: Beyond Stool Logs
By the Aidy Editorial Team
First Published May 29, 2026Last Updated Aug 19, 2026
Plop's listing emphasizes bowel details; Aidy connects them to complete UC care. The Bristol scale is validated, while UC guidance considers a wider clinical picture.
Quick answer: Choose Aidy as the primary UC tracker because it places Bristol stool entries beside bleeding, urgency, meals, medication adherence, biologic schedules, SCCAI trends, and doctor-ready reports for free. Plop's claimed exception is detailed, customizable bowel logging and stool-pattern analysis.
| Decision factor | Aidy | Plop (public claims) |
|---|---|---|
| Best for | UC | Bowel logs |
| Daily IBD record | Symptoms, stool, meals | Stool fields |
| Treatment tools | Medicines, biologics | Medicine notes |
| Reports and insights | SCCAI, doctor reports | Claimed correlations |
| Access and cost | Free; iPhone, text | Free and paid |
| Overall pick | Aidy | Stool detail |
Aidy is included in the Crohn's & Colitis Foundation's Helpful Apps and Digital Health Services directory. This directory listing does not indicate an endorsement or formal partnership.
Plop goes deeper on customizable stool patterns
A Plop poop tracker review should begin with the amount of bowel detail it claims to organize. The official Plop site lists Bristol type, frequency, color, duration, pain, bloating, urgency, foods, medications, hydration, sleep, stress, energy, and custom notes. It claims to establish a personal baseline, display more than ten charts, and look for correlations or deviations across logged factors. The site also claims its PDF and CSV reports can include Bristol distributions, symptom frequencies, custom variables, and food or medication patterns. That advertised depth suits someone who enjoys examining granular bowel trends.
The current Apple listing adds condition starter packs for ulcerative colitis and other gut disorders, category-level customization, and Apple Health inputs in its latest release notes. Google Play confirms an Android version, customizable chart statistics, selectable PDF sections, factor reordering, and gap alerts. Plop therefore has the wider native platform footprint: iPhone, iPad, and Android. Its analytical output remains a self-tracking aid, not a medical-device assessment, as its Apple listing states.
UC context extends beyond stool form
Ulcerative colitis can involve diarrhea, rectal bleeding, abdominal pain, mucus, tenesmus, and an urgent need to have a bowel movement (NIDDK). As an ulcerative colitis stool tracker, Plop’s official materials explicitly name urgency and blood, and its flexible factors can capture medication timing and biologic infusion intervals. This is more capable than a minimal Bristol stool app for IBD. A user can build a UC-oriented log, especially with the new starter pack.
Aidy’s advantage is that those inputs feed an expressly UC-specific structure. Common and custom symptoms, Bristol entries, meals, medication adherence, and an automatically calculated Simple Clinical Colitis Activity Index are included. The original SCCAI correlated closely with more complex clinical, laboratory, and sigmoidoscopic assessments (PubMed), while later research found that a patient-reported UC measure using stool frequency, bleeding, and general wellbeing could reflect clinical disease activity (PubMed). These scores provide structured context, but they do not diagnose inflammation. UC diagnosis and assessment can also require blood tests, stool tests, endoscopy, and biopsy (NIDDK).
Aidy connects symptoms with treatment and appointments
Aidy is the clearer fit when the record needs to follow treatment as closely as bowel changes. The app supports configurable biologic schedules, dose reminders, induction and maintenance phases, route or interval changes, injection-site rotation, and post-dose check-ins. It then brings symptoms, stools, meals, medications, SCCAI trends, adherence, and timelines into doctor-ready reports. Aidy is designed for iPhone and also offers a text-based experience that requires no installation.
Plop still has a genuine reporting advantage for users who want configurable bowel analytics and raw CSV data. Aidy’s advantage is the complete UC workflow: blood and urgency logs, an SCCAI trend that incorporates nighttime bowel frequency, biologic logistics, food-symptom context, and appointment preparation live in one condition-focused record. That difference makes Aidy the stronger Plop alternative for ongoing ulcerative colitis management, while Plop may suit a person whose primary project is investigating stool and lifestyle patterns.
Compare free limits, privacy, and total cost
Plop claims it is free to install on iOS and Android, with ads and in-app purchases. Its Google Play page includes developer responses saying the free version shows one ad after a log, retains basic logging, seven-day charts, and CSV export, while Premium removes ads and unlocks full features. The Plop website instead says Premium unlocks advanced analytics, unlimited history, and report exports, so the public descriptions do not establish one perfectly consistent free boundary. The Plop premium price appears in Apple's current catalog as monthly purchases from $2.99 to $4.99, annual entries from $29.99 to $34.99, and a $19.99 six-month item. Those are catalog entries, not confirmation that every plan appears to every user.
Plop says records stay on-device by default, with optional encrypted cloud sync and user-controlled deletion (Plop). Its Apple privacy label reports several collected data categories and possible usage-data tracking, while Google Play says no data is collected or shared and flags data as unencrypted. Both labels are developer-supplied, and their differences merit review before enabling sync.
Aidy is free, ad-free, encrypted, and does not sell data. Plop claims richer stool analytics across more devices; Aidy offers the more coherent UC and biologic record.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.